Engineering Biomaterials to Model Immune-Tumor Interactions In Vitro

Area of Science:

• Biomaterials Science
• Cancer Biology
• Immunology

Background:

• Traditional 2D cell cultures lack the complexity of the tumor microenvironment.
• Existing preclinical models often fail to account for immune cell interactions crucial for cancer drug efficacy.
• Low success rates in cancer drug clinical trials highlight limitations in current preclinical evaluation methods.

Purpose of the Study:

• To review the role of engineered biomaterial scaffolds in cancer research.
• To discuss the incorporation of tumor microenvironmental cues into biomaterial design for immune cell culture.
• To explore the potential of engineered tissues for precision oncological drug screening.

Main Methods:

• Review of literature on biomaterial scaffolds, tumor microenvironment, and cancer immunotherapies.
• Discussion of hydrogel design principles for culturing immune cells within biomaterials.
• Analysis of progress in developing engineered tissues for drug screening.

Main Results:

• Engineered biomaterial scaffolds can replicate key tumor microenvironmental cues.
• Hydrogel-based systems offer a platform for culturing diverse immune cells in a tumor context.
• These advanced in vitro models show promise for more accurate preclinical drug assessment.

Conclusions:

• Biomaterial scaffolds represent a significant advancement for in vitro cancer research.
• Incorporating immune cells into engineered tissues can enhance the relevance of drug screening models.
• Precision oncological drug screening using engineered tissues may improve the translation of cancer therapies from lab to clinic.